6-chloro-2,3-dihydro-1H-inden-5-amine | 858225-64-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 6-chloro-2,3-dihydro-1H-inden-5-amine
• CAS: 858225-64-6
• 化学式: C₉H₁₀ClN
• 分子量: 167.638
• InChiKey: GVNFSQOSVGQWNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-chloro-2,3-dihydro-1H-inden-5-amine 在 盐酸 、 sodium nitrite 、 tin(II) chloride dihydrate 作用下， 以 水 为溶剂， 以1.2 g的产率得到(6-chloro-2,3-dihydro-1H-inden-5-yl)hydrazine;hydrochloride
  参考文献：
  名称：

  ピラゾロピリミジン化合物及びその医薬用途

  摘要：

  ＮＬＲＰ３インフラマソーム阻害活性を有するピラゾロピリミジン化合物又はその製薬上許容される塩、それを含む医薬組成物、及びその医薬用途等が提供される。式［ＩＡ］の化合物又はその製薬上許容される塩（式中の各記号は明細書中で定義したとおりである）。

  公开号：

  WO2024048519A1
• 作为产物：
  描述：

  N1-(2,3-二氢-1H-茚-5-基)乙酰胺 在 盐酸 、 N-氯代丁二酰亚胺 、 palladium diacetate 、 对甲苯磺酸 作用下， 以 水 、 甲苯 为溶剂， 反应 76.0h， 生成 6-chloro-2,3-dihydro-1H-inden-5-amine
  参考文献：
  名称：

  COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS

  摘要：

  The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.

  公开号：

  WO2024121129A1

文献信息

• [EN] SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS<br/>[FR] ACIDES AMINO PHENYLACETIQUES SUBSTITUES, DERIVES DE CEUX-CI, PROCEDE POUR LES PREPARER ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE CYCLOOXYGENASE 2 (COX-2)
  申请人：NOVARTIS AG

  公开号：WO2004048314A1

  公开（公告）日：2004-06-10

  Compounds of formula (I) wherein R is hydrogen, lower alkyl, (C3-C8)cycloalkyl, hydroxy, halo, lower alkoxy, trifluoromethoxy, trifluoromethyl or cyano; and A is biaryl, optionally substituted β-naphthyl, bicyclic heterocyclic aryl, (C3-C6)cycloalkylmonocyclic carbocyclic aryl, or (C5 or C6)cycloalkane fused-monocyclic carbocyclic aryl; pharmaceutically acceptable salts thereof, and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders.

  式(I)中R为氢、较低的烷基、(C3-C8)环烷基、羟基、卤素、较低的烷氧基、三氟甲氧基、三氟甲基或氰基；A为联苯、可选择地取代的β-萘基、双环杂环芳基、(C3-C6)环烷基单环碳环芳基，或(C5或C6)环烷烃融合的单环碳环芳基；其药学上可接受的盐，以及其药学上可接受的酯；用于治疗COX-2依赖性疾病。
• Certain phenylacetic acids and derivatives
  申请人：——

  公开号：US20040132769A1

  公开（公告）日：2004-07-08

  Compounds of formula (I) 1 wherein R is hydrogen, lower alkyl, (C 3 -C 6 )cycloalkyl, hydroxy, halo, lower alkoxy, trifluoromethoxy, trifluoromethyl or cyano; and A is biaryl, optionally substituted &bgr;-naphthyl, bicyclic heterocyclic aryl, (C 3 -C 6 )cycloalkylmonocyclic carbocyclic aryl, or (C 5 or C 6 )cycloalkane fused-monocyclic carbocyclic aryl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders.

  化学式为(I)1的化合物，其中R为氢、低碳基、(C3-C6)环烷基、羟基、卤素、低烷氧基、三氟甲氧基、三氟甲基或氰基；而A为双芳基、可选取代的β-萘基、双环杂环芳基、(C3-C6)环烷基单环碳环芳基，或(C5或C6)环烷基融合的单环碳环芳基；其药学上可接受的盐和酯，可用于治疗COX-2依赖性疾病。
• Synthesis and Biological Evaluation of 2-Aryliminopyrrolidines as Selective Ligands for I₁ Imidazoline Receptors: Discovery of New Sympatho-Inhibitory Hypotensive Agents with Potential Beneficial Effects in Metabolic Syndrome
  作者：Vincent Gasparik、Hugues Greney、Stephan Schann、Josiane Feldman、Lyne Fellmann、Jean-Daniel Ehrhardt、Pascal Bousquet

  DOI：10.1021/jm501456p

  日期：2015.1.22

  New 2-aryliminopyrrolidines (1-18) were synthesized and tested for their binding properties on I-1 imidazoline receptors vs a2-adrenergic receptors and their blood pressure effects after both systemic and intracerebral administrations. The purposes of this study were: (i) to analyze structureactivity and affinity relationships on I-1 imdazoline receptors and (ii) to propose some leader compounds for the development of new sympatho-inhibitory drugs with potential applications in hypertension and/or metabolic syndrome, i.e., a cluster of cardiovascular (hypertension) and metabolic disorders. Our study highlights decisive arguments of SAR concerning both the affinity for I(1)Rs and the hypotensive activity of 2-aryliminopyrrolidines. Binding assays showed high affinity and selectivity of some compounds for I-1 imidazoline receptors over alpha(2)-adreergic receptors. Compound 13 (laboratory reference LNP599; K-i = 3.2 nM on I(1)imidazoline receptors) is the prototype for the development of new centrally acting agents targeting specifically I(1)imidazoline receptors to be used in the management of hypertension and/or metabolic syndrome.
• [EN] QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS<br/>[FR] COMPOSÉ QUINOLINAMINE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION DANS DES PRODUITS PHARMACEUTIQUES<br/>[ZH] 喹啉胺类化合物、其制备方法及其在医药上的应用
  申请人：JIANGSU HENGRUI PHARMACEUTICALS CO LTD

  公开号：WO2022247920A9

  公开（公告）日：2023-01-05
• SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS
  申请人：NOVARTIS AG

  公开号：EP1567477B1

  公开（公告）日：2009-09-09